Extracts of bixa inhibit glycation and AGEs formation in vitro

Journal of Medicinal Plants Research

Volumn 5, Issue 6, 2011, Pages 942-948

  Gutierrez, Rosa Martha Perez ^a   Baez, Efrén Garcia ^a   del Socorro López Cortez, Ma ^a   Cárdenas, Sofía Arellano ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Advanced glycation end product; Bixa; Carotenoids

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIXA ORELLANA EXTRACT; CHLOROFORM; FARNESYLACETONE; FRUCTOSAMINE; GERANYGERANYL ACETIC ACID; GERANYGERANYL FORMIC ACID; GERANYGERANYL OCTADECANOIC ACID; GERANYLGERANIOL; GLIBENCLAMIDE; GLUCOSE; INSULIN; PLANT EXTRACT; STREPTOZOCIN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIXA ORELLANA; BIXACEAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCATION; GLYCEMIC CONTROL; HYPERGLYCEMIA; IN VITRO STUDY; INHIBITION KINETICS; INSULIN BLOOD LEVEL; MALE; MUSCLE TISSUE; NONHUMAN; PLANT SEED; RAT; STREPTOZOCIN DIABETES;

BIXA; BIXA ORELLANA; RATTUS;

EID: 79955396452     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Sci., 232: 1629-1632.
2. Brownlee M, Cerami A, Vlassara H (1988). Advanced glycolation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318: 1315-1321.
3. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414: 813-820.
4. Bucala R, Cerami A (1992). Advanced glycosylation: chemistry, biology, and Implications for diabetes and aging. Adv. Pharmacol., 23: 1-34.
5. Fernandes AC, Almeida CA, Albano F, Laranja GA, Felzenszwalb I, Lage CL, Moura AS, Kovary K (2002). Norbixin ingestion did not induce any detectable DNA breakage in liver and kidney but caused a considerable impairment in plasma glucose levels of rats and mice. J. Nutr. Biochem., 13: 411-420.
6. Giuliano G, Rosati C, Barmley PM (2003). To dye or not to dye: biochemistry of annatto unveiled. Trends Biotech., 21: 513-516.
7. Hermann LS, Schersten B, Bitzen T, Kjellstrom F, Lindgarde F, Melandev A (1994). Therapeutic comparison of metformin and sulfonylurea, alone and various mechanism. Diabetes care, 17: 1100-1109.
8. Jakus V, Rietbrock N (2004). Advanced glycation end products and the progress of diabetic vascular complications. Physiol. Res., 53: 1131-1142.
9. Jondiko IJO, Pattenden G (1989). Terpenoid and an apocarotenoid from seeds of Bixa orellana. Phytochem., 28: 3159-3162.
10. Lee C, Yim MB, Chock PB, Yim HS, Kang SO (1998). Oxidationreduction properties of methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem., 273: 25272-25278.
11. Lunceford N, Gugliucci A (2005). Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia., 76: 419-427.
12. Mercadante AZ, Steck A, Pfander H (1997). Isolation and structure elucidation of Minor carotenoids from annatto (Bixa orellana L.) seeds. Phytochem., 46: 1379-1383.
13. Morrison EY, Thompson H, Pascoe K, West M, Fletcher C (1991). Extraction of an hyperglycemic principle from the annatto (Bixa orellana), a medicinal plant in the West Indies. Trop. Geogr. Med., 43: 184-188.
14. Rahbar S (2007). Novel inhibitors of glycation and AGE formation. Cell Biochem. Biophys., 48: 147-157.
15. Russell KR, Morrison EY, Ragoobirsingh D (2005). The effect of annatto on insulin binding properties in the dog. Phytother. Res., 19: 433-436.
16. Russell KR, Omoruyi FO, Pascoe KO, Morrison EY (2008). Hypoglycaemic activity of Bixa orellana extract in the dog. Methods Find Exp. Clin. Pharmacol., 30: 301-305.
17. Sang-Eun P, Mee-Hyun C, Jin Kyu L, Jong-Sang K, Jeong Hwan K, Dae Young K, Cheon-Seok P (2007). A New Colorimetric method for determining the isomerization activity of sucrose isomerase. Bioscience, Biotech. Bioch., 71: 583-586.
18. Tsunosue M, Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yamaguchi S (2010). An α-glycosidase inhibitor, acrabose treatment decreases serum levels of glyceraldehyde derived advanced glycation end products (AGEs) in pateints with type 2 diabetics. Clin. Exp. Med., 10: 139-141.
19. Yamagishi S, Imiazumi T (2005). Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Phrama. Design, 11: 2279-2299.